J.T. Greene

Delivery technologies for cancer immunotherapy

Engineered T cells: the promise and challenges of cancer immunotherapy

Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

Prospects for adoptive immunotherapy of pancreatic cancer using chimeric antigen receptor-engineered T-cells

IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas